InMode Ltd. (NASDAQ:INMD – Get Rating) has been given a consensus rating of "Buy" by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have covered the stock in the last year is $46.17.

INMD has been the subject of several research reports. TheStreet downgraded shares of InMode from a "b-" rating to a "c+" rating in a research report on Tuesday, September 20th. Barclays started coverage on shares of InMode in a report on Wednesday, December 21st. They set an "overweight" rating and a $44.00 target price on the stock. Finally, Jefferies Financial Group started coverage on shares of InMode in a report on Wednesday, October 12th. They set a "buy" rating and a $40.00 target price on the stock.

InMode Trading Up 7.9 %

INMD stock opened at $35.28 on Friday. The stock has a 50-day moving average price of $35.87 and a two-hundred day moving average price of $33.10. The stock has a market cap of $2.94 billion, a PE ratio of 17.04 and a beta of 2.19. InMode has a 1 year low of $20.60 and a 1 year high of $54.68.

Hedge Funds Weigh In On InMode

A number of hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in InMode by 122.3% during the 1st quarter. JPMorgan Chase & Co. now owns 79,333 shares of the healthcare company's stock worth $2,928,000 after acquiring an additional 43,646 shares during the period. Bank of New York Mellon Corp increased its position in InMode by 3.9% in the 1st quarter. Bank of New York Mellon Corp now owns 110,994 shares of the healthcare company's stock valued at $4,095,000 after buying an additional 4,217 shares in the last quarter. PNC Financial Services Group Inc. increased its position in InMode by 22.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 13,087 shares of the healthcare company's stock valued at $484,000 after buying an additional 2,416 shares in the last quarter. Natixis Advisors L.P. increased its position in shares of InMode by 6.1% during the first quarter. Natixis Advisors L.P. now owns 18,591 shares of the healthcare company's stock worth $686,000 after acquiring an additional 1,076 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in shares of InMode during the first quarter worth about $925,000. Institutional investors and hedge funds own 55.24% of the company's stock.

InMode Company Profile

(Get Rating)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

Further Reading

• Get a free copy of the StockNews.com research report on InMode (INMD)
• Cathie Wood Is Buying These Stocks, Should You?
• Thor Industries Hammered Its Numbers. Is it a Buy?
• Tritium Is the Largest DC EV Charger Maker You've Never Heard Of
• United Airlines Soars Ahead of Earnings...Time to Deplane?
• Is Dividend King PPG Industries A Buy Before Earnings?

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.